Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

President Trump’s executive order to lower drug prices through sweeping, cross-agency action left leaders in the ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 13, 2025 /EINPresswire.com/ -- The market for Huntington's disease has seen a sharp increase in recent years. It is estimated to grow from $0.47 billion in ...

President Trump signed an executive order aimed at lowering U.S. drug prices to match those of other countries, prompting ...

US President Donald Trump said Monday he would slash drug prices so they match those abroad, accusing Europe in particular of ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...